{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:01:23Z","timestamp":1794013283400,"version":"4.8.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T00:00:00Z","timestamp":1678492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research and development grant from Phyathai Hospital"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Elevated plasma cholesterol and\/or plasma triglyceride levels in nephrotic syndrome patients are the result of impaired lipoprotein clearance and a compensatory increase in hepatic lipoprotein synthesis. Plasma proprotein convertase subtilisin\/kexin type 9 levels directly correlate to the amount of proteinuria in nephrotic syndrome patients. Proprotein convertase subtilisin\/kexin type 9 monoclonal antibody has been used to treat dyslipidemia in some refractory nephrotic syndrome cases. As a therapeutic protein, proprotein convertase subtilisin\/kexin type 9 monoclonal antibody simply deteriorates if stored in inappropriate temperatures or conditions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>In this article, we present the case of a 16-year-old Thai\u00a0female with severe combined dyslipidemia secondary to refractory nephrotic syndrome. She received proprotein convertase subtilisin\/kexin type 9 monoclonal antibody (alirocumab) treatment. However, the drugs were mistakenly frozen in a freezer for up to 17\u00a0hours before being stored at 4\u00a0\u00b0C. After using two frozen devices, serum total cholesterol, free proprotein convertase subtilisin\/kexin type 9, and lipoprotein(a) significantly decreased. Nonetheless, the patient developed a skin rash 2\u00a0weeks after the second injection and the lesion spontaneously resolved without any treatment approximately 1 month later.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The effectiveness of proprotein convertase subtilisin\/kexin type 9 monoclonal antibody seems to be stable after being stored under freeze\u2013thaw conditions. However, improperly stored drugs should be discarded to avoid any potential undesirable side effects.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13256-023-03804-5","type":"journal-article","created":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T01:02:42Z","timestamp":1678496562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Injection of an improperly stored proprotein convertase subtilisin\/kexin type 9 monoclonal antibody in a patient with secondary dyslipidemia from nephrotic syndrome: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Tanawan","family":"Kongmalai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalinee","family":"Chuanchaiyakul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuttana","family":"Srinoulprasert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuntakorn","family":"Thongtang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,11]]},"reference":[{"issue":"1","key":"3804_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrneph.2017.155","volume":"14","author":"S Agrawal","year":"2018","unstructured":"Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE. Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol. 2018;14(1):57\u201370.","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"3804_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1161\/CIRCULATIONAHA.115.020912","volume":"134","author":"ME Haas","year":"2016","unstructured":"Haas ME, Levenson AE, Sun X, Liao WH, Rutkowski JM, de Ferranti SD, et\u00a0al. The role of proprotein convertase subtilisin\/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation. 2016;134(1):61\u201372.","journal-title":"Circulation"},{"issue":"1","key":"3804_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s12882-017-0644-0","volume":"18","author":"Y Awanami","year":"2017","unstructured":"Awanami Y, Fukuda M, Nonaka Y, Takashima T, Matsumoto K, Yamasaki M, et\u00a0al. Successful treatment of a patient with refractory nephrotic syndrome with PCSK9 inhibitors: a case report. BMC Nephrol. 2017;18(1):221.","journal-title":"BMC Nephrol"},{"issue":"1","key":"3804_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.xphs.2019.08.009","volume":"109","author":"Y Le Basle","year":"2020","unstructured":"Le Basle Y, Chennell P, Tokhadze N, Astier A, Sautou V. Physicochemical stability of monoclonal antibodies: a review. J Pharm Sci. 2020;109(1):169\u201390.","journal-title":"J Pharm Sci"},{"issue":"1","key":"3804_CR5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12944-021-01447-3","volume":"20","author":"T Kongmalai","year":"2021","unstructured":"Kongmalai T, Chuanchaiyakul N, Sripatumtong C, Tansit T, Srinoulprasert Y, Klinsukon N, et\u00a0al. The effect of temperature on the stability of PCSK-9 monoclonal antibody: an experimental study. Lipids Health Dis. 2021;20(1):21.","journal-title":"Lipids Health Dis"},{"issue":"20","key":"3804_CR6","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1001\/jama.2016.16292","volume":"316","author":"DS Kazi","year":"2016","unstructured":"Kazi DS, Moran AE, Bibbins-Domingo K. Cost-effectiveness of PCSK9 inhibitor therapy-reply. JAMA. 2016;316(20):2152.","journal-title":"JAMA"},{"issue":"2","key":"3804_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et\u00a0al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3804_CR8","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1159\/000442976","volume":"8","author":"JH Boyd","year":"2016","unstructured":"Boyd JH, Fjell CD, Russell JA, Sirounis D, Cirstea MS, Walley KR. Increased plasma PCSK9 levels are associated with reduced endotoxin clearance and the development of acute organ failures during sepsis. J Innate Immun. 2016;8(2):211\u201320.","journal-title":"J Innate Immun"},{"issue":"1","key":"3804_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ekir.2020.09.046","volume":"6","author":"E Jatem","year":"2021","unstructured":"Jatem E, Lima J, Montoro B, Torres-Bondia F, Segarra A. Efficacy and safety of PCSK9 inhibitors in hypercholesterolemia associated with refractory nephrotic syndrome. Kidney Int Rep. 2021;6(1):101\u20139.","journal-title":"Kidney Int Rep"},{"issue":"5","key":"3804_CR10","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/ki.1993.357","volume":"44","author":"P Stenvinkel","year":"1993","unstructured":"Stenvinkel P, Berglund L, Heimburger O, Pettersson E, Alvestrand A. Lipoprotein(a) in nephrotic syndrome. Kidney Int. 1993;44(5):1116\u201323.","journal-title":"Kidney Int"},{"issue":"4","key":"3804_CR11","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.jacc.2018.10.039","volume":"73","author":"M Szarek","year":"2019","unstructured":"Szarek M, White HD, Schwartz GG, Alings M, Bhatt DL, Bittner VA, et\u00a0al. Alirocumab reduces total nonfatal cardiovascular and fatal events: the ODYSSEY OUTCOMES trial. J Am Coll Cardiol. 2019;73(4):387\u201396.","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl 2","key":"3804_CR12","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13223-018-0289-y","volume":"14","author":"R Warrington","year":"2018","unstructured":"Warrington R, Silviu-Dan F, Wong T. Drug allergy. Allergy Asthma Clin Immunol. 2018;14(Suppl 2):60.","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"17","key":"3804_CR13","doi-asserted-by":"publisher","first-page":"E532","DOI":"10.1503\/cmaj.171315","volume":"190","author":"EM Abrams","year":"2018","unstructured":"Abrams EM, Khan DA. Diagnosing and managing drug allergy. CMAJ. 2018;190(17):E532\u20138.","journal-title":"CMAJ"},{"key":"3804_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.617770","volume":"9","author":"D Weber","year":"2021","unstructured":"Weber D, Hubbuch J. Temperature based process characterization of pharmaceutical freeze-thaw operations. Front Bioeng Biotechnol. 2021;9: 617770.","journal-title":"Front Bioeng Biotechnol"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03804-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-023-03804-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-023-03804-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T01:02:57Z","timestamp":1678496577000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-023-03804-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,11]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["3804"],"URL":"https:\/\/doi.org\/10.1186\/s13256-023-03804-5","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,11]]},"assertion":[{"value":"3 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient\u2019s legal guardian for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}